Compare · DAWN vs SLRX
DAWN vs SLRX
Side-by-side comparison of Day One Biopharmaceuticals Inc. (DAWN) and Salarius Pharmaceuticals Inc. (SLRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DAWN and SLRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- DAWN is the larger of the two at $867.6M, about 44.6x SLRX ($19.4M).
- Over the past year, DAWN is up 203.4% and SLRX is down 92.7% - DAWN leads by 296.0 points.
- DAWN has more recent analyst coverage (13 ratings vs 2 for SLRX).
- Company
- Day One Biopharmaceuticals Inc.
- Salarius Pharmaceuticals Inc.
- Price
- $21.52+0.14%
- $0.82+36.55%
- Market cap
- $867.6M
- $19.4M
- 1M return
- +0.70%
- -3.57%
- 1Y return
- +203.39%
- -92.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 13
- 2
Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Latest DAWN
- Amendment: SEC Form SCHEDULE 13G/A filed by Day One Biopharmaceuticals Inc.
- SEC Form 15-12G filed by Day One Biopharmaceuticals Inc.
- SEC Form 4 filed by Large owner Ai Day1 Llc
- CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- COO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Gen Counsel & Secretary Dubow Adam returned 72,694 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Holles Natalie C. returned 57,310 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Director Ramasastry Saira returned 40,485 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Josey John A. returned 72,292 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)
Latest SLRX
- SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)
- SEC Form 8-K filed by Salarius Pharmaceuticals Inc.
- SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting